On this page of StockholderLetter.com we present the latest annual shareholder letter from GLYCOMIMETICS INC — ticker symbol GLYC. Reading current and past GLYC letters to shareholders can bring important insights into the investment thesis.

 •  4/1/2024 Letter Continued (Full PDF)
 •  4/21/2023 GLYC Stockholder Letter
 •  More "Biotechnology" Category Stockholder Letters
 •  GLYC Benford's Law Stock Score = 53

GLYC Shareholder/Stockholder Letter Transcript:

ANNUAL REPORT | 2023
Transforming Lives
Glycobiology-based Therapeutics
T H R O U G H R E S I L I E N T I N N O VAT I O N
Glycobiology-based Therapeutics

GlycoMimetics is a late clinical-stage biotechnoloy company discovering and
developing glycobiology-based therapies for cancers and in   ammatory diseases.
Additional information may be found at www.glycomimetics.com.

Letter from Our President and Chief Executive Of   cer
Dear Shareholders and Friends,
In 2023, we achieved several signi   cant milestones that have positioned us for success as we continue
our journey to become a commercially focused organization. Over the past year we have furthered our
mission of advancing the science of glycobiology to address signi   cant unmet needs in people living with
acute myeloid leukemia (AML) and sickle cell disease (SCD).
Our lead drug candidate, uproleselan, continues to progress in clinical development. In the second
quarter of 2023, GlycoMimetics announced U.S. Food and Drug Administration (FDA) clearance of a
protocol amendment to our pivotal Phase 3 study of uproleselan in relapsed/refractory AML patients.
This amendment provided for a time-based analysis of the primary endpoint of overall survival after a
de   ned cutoff date of March 31, 2024 if the 295 survival events of the originally planned event-driven
analysis were not observed by that date. With the addition of the time-based analysis we now expect
topline results this quarter. Should the data be positive, we plan to submit a New Drug Application to
the FDA by year end 2024. The median follow-up for this trial is now greater than three years, which is
remarkable in AML studies and especially in relapsed and refractory disease. There is high unmet need
amongst AML patients for therapy that is mutation agnostic, and we are optimistic that uproleselan can
be a transformative therapy for this patient population.
Uproleselan is concurrently being studied across a broad range of patient populations, underscoring our
commitment to address the unique needs of individuals battling AML. Our collaborators at the National
Cancer Institute (NCI) Alliance for Clinical Trials in Oncology are advancing their Phase 2/3 study in
frontline newly diagnosed AML patients who are age 60 and above and    t for chemotherapy. Enrollment
of the Phase 2 portion of the study was completed in December of 2021. We look forward to sharing the
results of the planned interim analysis of event-free survival from the 267 patients enrolled in Phase 2 of
that study as they become available.
Furthermore, GlycoMimetics agreed with the European Medicines Agency on a Pediatric Investigational
Plan, which followed our prior agreement with the FDA in the second quarter of 2023 on an initial
Pediatric Study Plan. As part of these pediatric plans, we are pleased that our AML collaboration with the
NCI has been further expanded to include a Phase 1/2 pediatric study that is currently being conducted
by the Children   s Oncology Group Pediatric Early Phase Clinical Trials Network. The    rst patient in the
continued   

Letter from Our President and Chief Executive Of   cer
continued
Phase 1 portion has been dosed, and the study has an expected enrollment of 18 patients. The addition of
a second NCI sponsored study demonstrates the high level of scienti   c interest in E-selectin antagonism
and our    rst-in-class molecule, uproleselan.
Our ongoing partnerships pursuant to investigator-sponsored trials at MD Anderson Cancer Center,
University of California-Davis, Boston Children   s Hospital of the Dana Farber Cancer Institute, and
Washington University at St. Louis continue to explore the potential of uproleselan in additional patient
populations. By comprehensively evaluating uproleselan across newly diagnosed and relapsed/refractory
AML in pediatric and adult patients, we aim to maximize its therapeutic impact and understand the potential
broad clinical utility of the drug.
Beyond uproleselan, our highly potent E-selectin antagonist GMI-1687 is being developed as a potential
patient-controlled, point-of-care treatment for in   ammatory diseases, with initial focus on the treatment of
acute vaso-occlusive events, also commonly called pain crises, in SCD. In January 2024, we announced
that our    rst-in-human trial evaluating GMI-1687 had met its primary and secondary endpoints with no
dose limiting toxicities or safety signals. We look forward to completing analysis of the Phase 1a study
and presenting the results at a medical conference.
We are excited about the opportunities that lie ahead in 2024 and beyond. Our primary focus is on the
topline results from our pivotal Phase 3 study expected in the second quarter. We remain con   dent in our
pipeline of    rst-in-class drug candidates which have signi   cant commercial potential, our team   s ability to
execute, and the unwavering support of our shareholders as we continue our mission to rede   ne the future
of AML and in   ammatory diseases, such as SCD.
I would like to extend my sincere gratitude to our dedicated team, our valued shareholders, our trusted
partners, and the patients who have contributed to GlycoMimetics    journey thus far.
Sincerely,
Harout Semerjian
President and CEO



 4/1/2024 Letter Continued (Full PDF)